London's healthtech startup Hormona, which provides personalized solutions for diagnosing and managing hormonal imbalances in women, has raised $6.7 million in a seed funding round to launch its hormone tests.
- Launched in 2020 by Karolina Löfqvist and Jasmine Tagesson, Hormona is a healthtech company that develops digital tools and hardware to help women monitor, understand, and manage hormonal fluctuations.
- The company’s flagship product is a hormone tracking app that enables users to log their menstrual cycles, symptoms, and general well-being. Using user-inputted data and algorithmic analysis, the app identifies patterns and delivers insights into hormone-related health changes.
- In addition to its core app, Hormona is developing a dedicated platform for women going through perimenopause, as well as a home testing device designed to measure estrogen levels. These products are developed in collaboration with medical experts in endocrinology, gynecology, and nutrition.
- Headquartered in London and Stockholm, Hormona employs a team of 12, and its tools are currently used by women in more than 185 countries.
Details of the deal
- The seed funding round was led by Helsinki-based Voima Ventures and co-led by London’s Supernode Global VC.
- The round also saw participation from DLF Ventures, as well as returning investors Nascent Invest from Sweden and US-based accelerator Techstars.
- With the fresh capital raised, Hormona plans to launch its at-home hormone testing device, expand its suite of digital health tools, including a perimenopause app, and scale internationally.
"This funding marks a pivotal step in Hormona’s journey and it’s a powerful show of trust from a world-class group of partners who share our vision. With this funding, we’re continuing to push the boundaries of science and technology, and build a team that’s as bold as our mission," Hormona's team, commented on LinkedIn.
- The funding will also support team growth, further scientific research, and clinical validation to enhance the platform’s accuracy and accessibility.
